Delivery Order HHSN261201500039I-HHSN26100002
Award Date
9/24/15
Potential Completion Date
9/23/18
Potential Value
$680K
Federal Agency
National Cancer Institute
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
New York, NY 10065, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a definitive cost-no-fee contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Cancer Institute to Weill Medical College of Cornell University, a private research university, for preclinical in vitro and in vivo screening assays to support the development of cancer preventive agents. The contract has a potential value of $36,289,060.27 and a completion date of October 31, 2012. It is not set aside for any specific business...
This federal contract award was made by the National Cancer Institute to Weill Medical College of Cornell University, a prestigious private research university, to provide services related to the testing of combination immuno and chemoprevention strategies for Lynch syndrome gastrointestinal cancer. The contract is a Delivery Order under the PREVENT Cancer Program (PREVENT) Indefinite Delivery Contract (IDC), which has a ceiling value of $149,995,000 and enables Weill Medical College to...
This federal contract award, with an ID of HHSN261201500039I|HHSN26100004, was issued by the National Cancer Institute (NCI) to the Weill Medical College of Cornell University. The $1,246,582.34 Firm Fixed Price award is for the development of an anti-Fusobacterium nucleatum vaccine for colorectal cancer immunoprevention. This contract is part of the NCI's PREVENT Cancer Preclinical Drug Development Program, a multiple-award Indefinite Delivery Contract (IDC) with a $149,995,000 ceiling...
Weill Medical College of Cornell University was awarded a delivery order against the PREVENT Cancer Program (PREVENT) multiple award IDIQ by the National Cancer Institute, an agency of the Department of Health and Human Services. The delivery order has a potential value of $891,983.59 to support the development of a Frameshift Peptide Vaccine for the Prevention of Lynch Syndrome-Associated Gastrointestinal Cancer. No set-aside designation was used for this award. The period of performance is...
This is a delivery order under the Preclinical Agent Development Assays 2012-2016 Indefinite Delivery Contract (IDC) awarded by the National Cancer Institute (NCI) to the Weill Medical College of Cornell University. The order is for $614,987.25 and covers preclinical in vitro and in vivo agent development assays and blood-based biomarkers of obesity-induced breast inflammation. This work supports the NCI's PREVENT Cancer Preclinical Drug Development Program, which aims to transition cancer...
This is a delivery order contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services, to The Institute for Cancer Research, a non-profit research organization and subsidiary of Temple University. The $988,252 firm fixed price contract is for research and development services in the area of biomedical basic research, specifically preclinical efficacy and biomarker analysis to support the NCI's PREVENT Cancer Preclinical Drug Development Program....
This is a $547,860 delivery order contract awarded by the National Cancer Institute (NCI) of the Department of Health and Human Services (HHS) to The Institute for Cancer Research, a non-profit research organization. The contract is part of the Preclinical Efficacy and Intermediate Endpoint Biomarkers indefinite delivery vehicle, which supports the PREVENT Cancer Preclinical Drug Development Program. Under this 5-year IDIQ, The Institute for Cancer Research provides preclinical efficacy...
This federal contract award was issued by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to The Institute for Cancer Research, a non-profit organization and subsidiary of Temple University. The $1,570,991.00 task order is part of the PREVENT Preclinical Drug Development Program, which focuses on preclinical efficacy and intermediate endpoint biomarker testing for cancer prevention drug candidates. The task order is for a project titled...
The provided information describes a federal contract award to Weill Medical College of Cornell University, a prestigious private research university. The contract, with an award value of $9,437,194.06, is for biomedical research services and is managed by the National Heart, Lung, and Blood Institute, a civilian agency within the National Institutes of Health. The contract is a definitive contract with a cost-no-fee pricing type, indicating it is for the delivery of specific research...
The Institute For Cancer Research, a non-profit subsidiary of Temple University, has been awarded a $884,185.34 firm fixed price delivery order against the National Cancer Institute's PREVENT Cancer Program multiple award indefinite delivery contract vehicle. This delivery order focuses on continued evaluation of candidate chemopreventive and immunopreventive regimens in support of the PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS through...